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TECHNICAL REPORT
In vitro ACTIVITY OF THE CLINICAL PULMONARY SURFACTANT SURFACEN® 
AGAINST Leishmania amazonensis
Odalys BLANCO(1), Yuliannis LUGONES(1), Elaine DÍAZ(1) & Lianet MONZOTE(2)
SUMMARY
Surfacen® is an exogenous natural lung surfactant, composed by phospholipids and hydrophobic proteins, which is applied 
successfully in Newborn Respiratory Distress Syndrome. In this paper, in vitro activity of Surfacen® against Leishmania amazonensis 
is described. The product showed activity against the amastigote form found in peritoneal macrophages from BALB/c mice, with 
an IC50 value of 17.9 ± 3.0 µg/mL; while no toxic effect on host cell was observed up to 200 µg/mL. This is the first report about the 
antileishmanial activity of Surfacen®.
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Leishmaniasis refers to a spectrum of diseases ranging from self-
healing cutaneous lesion to debilitating mucocutaneous and lethal 
visceral infections. It is estimated that more than 12 million people are 
affected by leishmaniasis, and 350 million people are at risk, making 
Leishmania one of the most important parasitic diseases. Since there is 
no antileishmanial vaccine in clinical use, control of leishmaniasis relies 
almost exclusively on chemotherapy. Treatment of leishmaniasis is still 
complicated, due to the occurrence of different causative species and 
various clinical manifestations. For almost seven decades, pentavalent 
antimonials constituted the standard antileishmanial treatment worldwide. 
However, in the last 15 years, their clinical value has been jeopardized 
due to the widespread emergence of resistance10.
In recent years, there has been a growing interest in alternative 
therapies such as the use of natural products6. Surfacen® is an exogenous 
natural lung surfactant, which has been applied successfully in Newborn 
Respiratory Distress Syndrome since 1990. The action mechanism of the 
exogenous surfactants is by replacing the missing endogenous surfactants. 
They accomplish this by reducing alveolar surface tension, increasing 
lung compliance, and stabilizing the alveoli to prevent atelectasis at end 
expiration8. Besides its property, the lung surfactant also plays a major 
role in the pulmonary defense, preventing the access of pathogens through 
the large alveolar surface exposed to the environment16.
Recently, the antimicrobial effect of Surfacen® has been demonstrated 
against infectious agents; particularly as an antibacterial agent3. The aim 
of the present study was to assess the potential antileishmanial activity of 
Surfacen®. In addition, cytotoxicity in macrophage was tested.
The strain of L. amazonensis (MHOM/77BR/LTB0016) was kindly 
provided by the Department of Immunology, Oswaldo Cruz Foundation, 
Brazil. The parasites were routinely isolated from mouse lesions and 
maintained as promastigotes at 26 ºC in Schneider’s medium (Sigma 
Chem Co, St. Louis, Mo, USA), containing 10% heat inactivated fetal 
bovine serum (Sigma), 200 U penicillin/mL and 200 g streptomycin/mL 
(Sigma). The parasites were not used after the fifth passage.
Surfacen® was supplied by CENSA (Havana, Cuba). The preparation 
was suspended at 20 mg/mL of phospholipids in distilled water. 
Meglumine antimoniate (SbV) (Glucantime®), obtained from the Rhône-
Poulenc Rorer, Mexico, was used as a reference drug.
Antipromastigote activity: Eleven concentrations of the products were 
assayed in quadruplicate. Exponentially growing cells (105 promastigotes/
mL, 199 mL) were distributed in 96-well plates. One microliter of each 
concentration of the product was added between 0.2 and 200 mg/mL, 
to a final volume of 200 mL and then incubated at 26 ºC for 72 h. A 
distilled water control was included in each experiment. After three days 
of exposure, the parasite was incubated with p-nitrophenyl phosphate 
(20 mg/mL) dissolved in buffer of sodium acetate 1M (BDH, Poole, 
England), pH 5.5, with 1% Triton X-100 (BDH, Poole, England) at 37 ºC 
for 3h. The absorbance was determined in an EMS Reader MF Version 
2.4-0, at a wavelength of 405 nm4. The endpoint was considered as the 
absorbance below of 3.0.
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Antiamastigote activity: Macrophages were harvested from peritoneal 
cavities of normal BALB/c mice in RPMI medium (Sigma). A volume of 
one mL of cells were plated at 106/mL and incubated at 37 ºC under an 
atmosphere of 5% CO2 for two hours. Non-adherent cells were removed 
and stationary-phase L. amazonensis promastigotes were added at a 
4:1 parasite/macrophage ratio. The cultures were incubated for four 
hours, washed to remove free parasites and 10 µL of different drug 
concentrations were added between 6.25 and 50 µg/mL, in duplicate, 
for 48 h. Control cultures treated with 10 µL of distilled water were 
included. The cultures were then fixed with absolute methanol, stained 
with Giemsa, and examined under light microscopy15. The number of 
intracellular amastigotes and the percentage of infected macrophage 
were determined in 100 macrophages. The infection rates were obtained 
by multiplying the percentage of infected macrophages by the number 
of amastigotes per infected macrophages. The results were expressed 
as percent of reduction of the infection rate (%IR) in comparison with 
that of the controls and the IC50 was determined by lineal regression7.
Cytotoxicity assay: The cytotoxicity of the compound was 
determined on mouse peritoneal macrophages, which are the host cells 
for the amastigote form of the parasite. The monocell layer of peritoneal 
macrophage was treated at concentrations between 0.2 and 200 µg/mL for 
48 hours. The viability was determined using the colorimetric assay with 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) 
(SIGMA, St. Louis, MO, USA). MTT solutions were prepared at 5 mg/
mL and added to each well. After an additional three hours incubation, 
the formazan crystals were dissolved by adding 100 µL DMSO. The 
optical density was determined using an EMS Reader MF, Version 2.4-0, 
at a test wavelength of 560 nm and a reference wavelength of 630 nm14.
The results were compared by Mann-Whitney test using the Statistical 
for Windows Program (Release 4.5, StatSoft, Inc. 1993). Statistical 
differences were considered when p < 0.05.
Surfacen® showed activity against intracellular amastigotes forms, 
inhibiting the percent of infected macrophage and the average number 
of amastigotes per macrophage (Fig. 1A). The IC50 value against parasite 
was of 17.9 ± 3.0 µg/mL; while no toxic effect on mice macrophage 
Fig. 1 - Percent of infected macrophage and the average number of amastigotes per macrophage in treated L. amazonensis-infected mouse peritoneal macrophage. Results are from three 
experiments in duplicate and are shown as percentages and standard deviations. A: treatment with Surfacen®; B: treatment with Glucantime; *: Statistical differences compared with untreated 
cells (p < 0.05). 
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was observed at the highest concentration evaluated (200 µg/mL). The 
product showed a similar activity (p > 0.05) to a drug used as first line, 
glucantime, which showed an IC50 value of 11.0 ± 3.4 µg/mL (Fig. 1B). 
Similar results are found with other drugs used in clinical studies such 
as posaconazole, which has decreased the survival of L. amazonensis 
amastigotes in 50 % at 16 µg/mL1.
This surfactant did not cause inhibitory activity on promastigote 
forms of the parasite (results not shown). The specific activity observed 
on the intracellular form could be a consequence of the direct action 
of the compounds on probable specific targets on the amastigote, or 
an interference with defense mechanisms of the amastigote within the 
hostile environment of the macrophage. The pentavalent antimonials, 
drugs of the first line, do not show activity against the promastigotes, 
but they are active against the amastigote form, because the drug is 
transformed into the active compound, the trivalent antimonials, in 
the host cell13.
The mechanism by which Surfacen® kills Leishmania is still 
unknown. Surfacen®, as another clinical lung surfactant, is a complex 
mixture composed by phospholipids and specific proteins, called 
surfactant proteins (SP) B and C. It has been suggested that SP-B has 
important and significant homologies with some eukaryotic antibiotic 
peptides and, in fact, it has been demonstrated that a synthetic SP-B-
like peptide inhibits the growth of Escherichia coli cultures9. Recently, 
it has also been demonstrated that SP-B and SP-B-related peptides 
induce aggregation and death of bacteria in clinical isolates of Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and 
group B Streptococcus. It was related that this protein promoted increase 
of the permeability of bacterial membranes12. These authors showed that 
antimicrobial activity of SP-B was inhibited by surfactant phospholipids; 
however, Curosurf, a clinical pulmonary surfactant with similar 
composition to Surfacen®, was bactericidal to group B streptococcal and 
E. coli strains5. Additionally, several virulence properties of GBS®-h/c 
can be blocked by dipalmitoyl phosphatidylcholine (DPPC), the major 
phospholipid component of the pulmonary surfactant11. SP-B is a member 
of the saposin-like proteins (SAPLIP), which include potent antimicrobial 
peptides such as Nk-lysin, a peptide with antimicrobial and cytolitic 
activities. All SAPLIPs interact with lipids and have membranolytic 
activity2,12. Recently, it was demonstrated the presence of a proSPB-
derived saposin-like protein with antimicrobial activity at acidic pH 
in the lung surfactant. It was proposed to stimulate defense actions by 
macrophages17. All these findings could support the antipathogenic 
actions found in Surfacen®.
In conclusion, this is the first report about the antileishmanial activity 
of Surfacen®. Its effects and low toxicity suggest that this product could 
be explored in the design of new molecules against Leishmania parasite. 
Further experiments must be performed in animal models to corroborate 
the potential antileishmanial activity of Surfacen®.
RESUMEN
Actividad in vitro de surfactante pulmonar clínico Surfacen® 
frente a Leishmania amazonensis
Surfacen® es un surfactante natural exógeno extraído del pulmón, 
formado por fosfolípidos y proteínas hidrofóbicas, el cual es aplicado 
con éxito en el Síndrome de Distrés Respiratorio en Niños Recién 
Nacidos. En este trabajo, se describe la actividad in vitro del Surfacen® 
contra Leishmania amazonensis. El producto mostró actividad frente 
a amastigotes que se encuentran en macrófagos peritoneales de ratón 
BALB/c, con una CI50 de 17.9 ± 3.0 µg/mL, mientras no se observaron 
efectos tóxicos sobre la célula hospedera hasta 200 µg/mL. Este estudio 
constituye el primer reporte sobre la actividad antileishmania del 
Surfacen®.
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